TCS Catheter Lock Solution

….an Anti-Microbial Lock Solution providing patency and infection control

….a revolutionary approach to catheter maintenance

The Researchers New Best Friend

Components :

TCS combines two active ingredients vital to the effective management of vascular access catheters – Taurolidine and Citrate. When catheters are locked with TCS, their internal flow passages are resistant to clot formation & hostile to bacterial and fungal growth.


  • – chemically modified amino acid taurine
  • – inhibits biofilm that can allow protected microbial colonization
  • – prevents intraluminal microbial colonization
  • – interacts with components of microbial cell resulting in irreparable injury
  • – acts effectively against a broad range of bacteria and fungi
  • – does not induce development of resisitant microbes


  • – anticoagulant component of TCS
  • – forms a complex with calcium in the blood, disrupting the normal coagulation cascade
  • – inhibits intraluminal blood coagulation with no systemic effect
Advantages :

Prevention of catheter related infection

Taurolidine has broad spectrum antimirobial activity against gram-positive and gram-negative bacteria,yeast and fungi

Reduced risk of biofilm formation

Taurolidine causes a loss of microbial fimbriae and flagellae, altering the microbial surface, preventing colonization

Supports catheter patency

The citrate ion chelates calcium ions in the blood by forming calcium citrate an complexes, disrupting the clotting mechanism.

No development of resistance

Taurolidine has broad spectrum antimirobial activity against gram-positive and gram-negative bacteria, yeast and fungi

Favorable safety profile

No systemic nor toxic effects of Taurolidine have been identified. Its’ safety has been an confirmed in clinical studies with long term intravenous

Bibliography :

Betjes M. et. al. “Preventions of dialysis catheter-related and sepsis with a citrate -taurolidine-containing lock solution”. 2004

Koldenhoff M. et. al. “Taurolidine is effective in an the treatment of central venous catheter-related bloodstream infections in cancer patients”. 2004

Jurewitsch B .et. al. “Taurolidine Lock: the key to prevention of recurrent catheter-related bloodstream infections”. 2005

Mandolfo S. et. al. “Catheter lock solutions:it’s time for a change.” 2006

Bradshaw JH. et. al. “Taurolidine and catheter related bloodstream Infection: A systematic review of the literature”. 2008

Simon A. et. al. “Taurolidine-citrate lock solution significantly reduces CVAD-associated gram-positive infections in pediatric cancer patients”. 2008

Download Our Latest Catalog

Catalog form